Impact of COVID-19 on Economy, Industry and Company :
The emergence of novel coronavirus has affected the global economy, industry dynamics and company’s top line. The entire ecosystem has to suffer the impact of this pandemic disease which would result in significant demand & supply gap, production delay and weak consumer demand of end products across industries. At Bizizz Market Research, our analyst has done extensive research across industries and identify various methodologies which would assist C-Level executive to counter this ongoing threat and make informed business decision.
Kindly contact us to know more details: https://www.bizizzmarketresearch.com/contact
Global IBD Treatment Market was Valued at US$ 16.59 Bn in 2019 and it is Expected to Reach More than US$ 24.4 Bn by 2028, Likely to Grow with the CAGR of 4.4% During the Forecast Period.
Inflammatory bowel disease is an assemblage of medical disorders that induces chronic pain in the digestive region. IBD is a hypernym that includes two major diseases; Crohn’s disease and ulcerative colitis. The precise origin of IBD is not comprehended yet; despite, genetic factors, autoimmune ailments, and lifestyle shifts are speculated to generate the signs of inflammatory bowel disease in a person.
Existence Of Resilient Pipeline Drugs For The Therapy Of Inflammatory Bowel Disease (IBD) Is Estimated To Propel The Demand for IBD Treatment Over The Forecast Period.
The precise origin of IBD is not identified yet; though, researchers estimate the combination of various circumstances such as hereditary factors, smoking, toxic lifestyles, autoimmune disorders, and environment that commence to the increase of manifestations of IBD. Excessive dosage and everyday management of medicines to heal numerous chronic, as well as contagious ailments, profess the danger of promoting IBD. Further, the dosage of non-steroidal anti-inflammatory medications such as ibuprofen and aspirin double the hazard of evolving IBD. All these factors are expected to power the IBD Market.
The emergent elderly populace is anticipated to positively influence the global market. On the word of an article released in 2018 in the U.S. government’s Census Bureau, it is assessed that by 2035, the people aged 65 years old and above are probable to extent 78 MN, while children under the age of 18 might be around 76.7 Mn. This rise in the population is also stimulating the IBD Market.
Moreover, major corporations such as Pfizer Inc.; AbbVie Inc. Johnson & Johnson Services Inc.; and Takeda Pharmaceutical Company Limited; are majorly involved in product research and development and this is also considered as one of the chief driving factors for the IBD market.
Crohn’s disease was a Key subdivision in 2019
Ulcerative colitis and Crohn’s disease are the two main categories of IBDs. Crohn’s disorder was the biggest fragment in the year 2019 as a result of the cumulative frequency of the disorder. As stated by an article put out by the Jobson Medical Information LLC, the number of Crohn’s disease's sufferer was ascertained to remain around 3.2 to 14.5 instances per 100,000 people each year and the occurrence was approximately 200 cases per 100,000 grownups in the United States.
Ulcerative colitis is estimated to be the fastest-growing subdivision in type segment over the forecast year as consequence of the presence of robust pipeline drugs for its medication. Furthermore, the growing participation of important companies in therapeutic improvement associated with the field is estimated to propel the subdivision. Johnson & Johnson Services Inc. announced new data in the year 2019 from its Phase 3 protocol (UNIFI) study displaying optimistic outcomes of STELARA in grownups suffering from moderate to severe ulcerative colitis.
Based on the route of administration, the IBD Market is divided into injectables and oral routes. Injectables are dignified to be the major subdivision because of their effectiveness. Additionally, the development of biosimilars, for instance, Inflectra is anticipated to propel subdivision evolution. Moreover, the oral route is valued to be the fastest developing subdivision over the assessment interval as a result of the existence of resilient pipeline drugs. The oral subdivision is further classified into JAK inhibitors, corticosteroids, and ASAs. ASAs conquered the market in 2019 and JAK inhibitors are assessed to be the fastest developing sector over the evaluation timeframe.
Based on the distribution channel, the IBD treatment market is classified into retail pharmacy, online pharmacy, and hospital pharmacy. The hospital pharmacy subdivision, which consists of both out-patient and in-patient, led the market with a stake of 36.5% in the year 2019. Furthermore, online pharmacy is assessed to be the fastest rising subdivision over the assessment interval. The tendency of online buying and the requisition for it is increasing because of suitability, suppleness, and ease, which is growing the revenue produced by this subdivision. Additionally, online shopping provides several concessions, which further profit buyers. These factors are anticipated to drive the market for online pharmacies over the evaluation period.
North America held a significant share in the global IBD Treatment Market during the Forecast Period
North America dominated the global IBD treatment market in 2019 as a result of the existence of important corporations and a well-developed healthcare set-up. The North American region is expected to uphold its supremacy over the evaluation period as a result of the growing elderly populace base and occurrence of Crohn’s disease and ulcerative colitis. Moreover, as stated by an article put out by the Jobson Medical Information LLC, the number of Crohn’s disease's sufferer was ascertained to remain around 3.2 to 14.5 instances per 100,000 people each year and the occurrence was approximately 200 cases per 100,000 grownups in the United States.
Asia Pacific is projected to be the fastest emergent regional market over the evaluation interval as a result of escalating medications endorsements, a large number of patients suffering from IBD disease in Australia, China, New Zealand, and India, because of the escalation in disposable medical disbursement, and an upsurge in access to healthcare.
Several organizations are concentrating on organic development approaches such as product approvals, and product launches and others for instance events and patents. Inorganic development approach observed in the market were merger and acquisitions, and collaborations, partnership. These activities have concreted the way for the improvement of business and customer base of market players. The leading companies from IBD Market are estimated to have beneficial evolution prospects in the future with the escalating requisition for IBD Market in the worldwide market.
Some of the significant corporations in the market are Celltrion Healthcare Co., Ltd.; Pfizer Inc.; Gilead Sciences, UCB S.A.; AbbVie Inc.; CELGENE CORPORATION; COSMO PHARMACEUTICALS; Innovate Biopharmaceuticals; Takeda Pharmaceutical Company Limited; and Johnson & Johnson Services Inc.
Global IBD Market by Type
- Crohn’s disease
- Ulcerative colitis
Global IBD Market by Route of Administration
- IL inhibitors
- JAK inhibitors
Global IBD Market by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global IBD Market by Region
- North America
- Asia Pacific
- Latin America
- Middle East and Africa